EP4101452A4 - Verwendung von 4-aminochinolinverbindungen zur behandlung von coronavirusinfektionen - Google Patents

Verwendung von 4-aminochinolinverbindungen zur behandlung von coronavirusinfektionen Download PDF

Info

Publication number
EP4101452A4
EP4101452A4 EP20917330.1A EP20917330A EP4101452A4 EP 4101452 A4 EP4101452 A4 EP 4101452A4 EP 20917330 A EP20917330 A EP 20917330A EP 4101452 A4 EP4101452 A4 EP 4101452A4
Authority
EP
European Patent Office
Prior art keywords
coronavirus infections
aminoquinoline compounds
treat
treat coronavirus
aminoquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20917330.1A
Other languages
English (en)
French (fr)
Other versions
EP4101452A1 (de
Inventor
Wu Zhong
Gengfu Xiao
Zhihong HU
Manli Wang
Leike ZHANG
Ruiyuan CAO
Wei Li
Shiyong FAN
Xinbo Zhou
Song Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academy of Military Medical Sciences AMMS of PLA
Original Assignee
Academy of Military Medical Sciences AMMS of PLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academy of Military Medical Sciences AMMS of PLA filed Critical Academy of Military Medical Sciences AMMS of PLA
Publication of EP4101452A1 publication Critical patent/EP4101452A1/de
Publication of EP4101452A4 publication Critical patent/EP4101452A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20917330.1A 2020-02-03 2020-06-02 Verwendung von 4-aminochinolinverbindungen zur behandlung von coronavirusinfektionen Withdrawn EP4101452A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010078808 2020-02-03
PCT/CN2020/093989 WO2021155651A1 (zh) 2020-02-03 2020-06-02 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用

Publications (2)

Publication Number Publication Date
EP4101452A1 EP4101452A1 (de) 2022-12-14
EP4101452A4 true EP4101452A4 (de) 2024-02-21

Family

ID=72384927

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20917330.1A Withdrawn EP4101452A4 (de) 2020-02-03 2020-06-02 Verwendung von 4-aminochinolinverbindungen zur behandlung von coronavirusinfektionen

Country Status (5)

Country Link
US (1) US20230218606A1 (de)
EP (1) EP4101452A4 (de)
JP (1) JP2023512093A (de)
CN (1) CN111658648A (de)
WO (1) WO2021155651A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658648A (zh) * 2020-02-03 2020-09-15 中国人民解放军军事科学院军事医学研究院 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用
CN113633635B (zh) * 2021-08-27 2023-01-10 中国药科大学 一种用于治疗新型冠状病毒感染肺炎的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194970A1 (en) * 2020-03-23 2021-09-30 Hazan Sabine Methods of preventing and treating covid-19 infection
EP3892275A1 (de) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolisierung von hcq oder dessen metaboliten zur behandlung von lungeninfektionen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161821A0 (en) * 2001-11-09 2005-11-20 Lauren Charous Pharmaceutical compositions containing an aminoquinoline or a hydroxyquinoline derivative
CN103027915A (zh) * 2011-09-29 2013-04-10 中国医学科学院基础医学研究所 氯喹治疗和氯丙嗪预防肺感染和损伤的用途
US10434116B2 (en) * 2014-04-07 2019-10-08 University Of Maryland, Baltimore Methods of treating coronavirus infection
CN111658648A (zh) * 2020-02-03 2020-09-15 中国人民解放军军事科学院军事医学研究院 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021194970A1 (en) * 2020-03-23 2021-09-30 Hazan Sabine Methods of preventing and treating covid-19 infection
EP3892275A1 (de) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolisierung von hcq oder dessen metaboliten zur behandlung von lungeninfektionen

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Is hydroxychloroquine a treatment for COVID-19 ?", 26 September 2023 (2023-09-26), XP093117935, Retrieved from the Internet <URL:https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/hydroxychloroquine-treatment-covid-19/art-20555331> [retrieved on 20240110] *
CHEN J ET AL: "A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19", ZHEJIANG DA XUE XUE BAO YI XUE BAN., vol. 49, no. 2, 25 May 2020 (2020-05-25), pages 215 - 219, XP093117932, DOI: 10.3785/j.issn.1008-9292.2020.03.03 *
GAUTRET PHILIPPE ET AL: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial", MEDRXIV, 20 March 2020 (2020-03-20), XP055953042, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.03.16.20037135v1.full.pdf+html> [retrieved on 20220819], DOI: 10.1101/2020.03.16.20037135 *
GENTILE DAVIDE ET AL: "New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 16, 1 January 2020 (2020-01-01), pages 1 - 16, XP055946547, DOI: 10.3390/ijms21165856 *
See also references of WO2021155651A1 *
VINCENT MARTIN J ET AL: "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, vol. 2, no. 1, 22 August 2005 (2005-08-22), pages 69, XP021010915, ISSN: 1743-422X, DOI: 10.1186/1743-422X-2-69 *
WRIGHT CHRISTOPHER ET AL: "Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?", EVIDENCE-BASED DENTISTRY, NATURE PUBLISHING GROUP UK, LONDON, vol. 21, no. 2, 1 June 2020 (2020-06-01), pages 64 - 65, XP037493584, ISSN: 1462-0049, [retrieved on 20200626], DOI: 10.1038/S41432-020-0098-2 *

Also Published As

Publication number Publication date
US20230218606A1 (en) 2023-07-13
WO2021155651A1 (zh) 2021-08-12
EP4101452A1 (de) 2022-12-14
CN111658648A (zh) 2020-09-15
JP2023512093A (ja) 2023-03-23

Similar Documents

Publication Publication Date Title
EP3854403C0 (de) Verwendung von substituierten aminopropionsäureverbindungen zur behandlung von sars-cov-2-infektion
EP4157466A4 (de) Verwendung von ezh2-inhibitoren zur behandlung von krebs
EP4373480A4 (de) Behandlung von depression
EP4157272C0 (de) Remdesivir zur behandlung von viralen infektionen
EP4426682A4 (de) Sars-cov-2-inhibitoren zur behandlung von coronavirusinfektionen
EP4157255A4 (de) Behandlung von coronavirus
EP4440574A4 (de) Verwendung von pipendoxifen zur behandlung von sars-cov-2-infektionen
EP4359405A4 (de) Beta-lactam-derivate zur behandlung von krankheiten
EP4352231A4 (de) Behandlung von angptl4-bedingten erkrankungen
EP4392413A4 (de) Behandlung von neuroinflammatorischen erkrankungen
EP4447973A4 (de) Verwendung einer kombinationstherapie zur behandlung von krebs
EP4463157C0 (de) Behandlung von gm2-gangliosidose
EP4096675C0 (de) Zusammensetzungen zur behandlung von long covid
EP4392423A4 (de) Chinazolinverbindungen zur behandlung von krankheiten
EP4436667C0 (de) Piperazinylsulfonylarylverbindungen zur behandlung von bakteriellen infektionen
EP4413032A4 (de) Behandlung von mastzellenbedingten erkrankungen
EP4101452A4 (de) Verwendung von 4-aminochinolinverbindungen zur behandlung von coronavirusinfektionen
EP4305043A4 (de) Reinigung von sialooligosacchariden
EP4326277A4 (de) Verfahren zur behandlung von ösophagusstrikturen
EP4110344A4 (de) Verwendung von thyromimetika zur behandlung von krebs
EP3943110C0 (de) Verwendung von photosensibilisatoren zur behandlung von viralen atemwegsinfektionen
EP4142728C0 (de) 6&#39;-methoxycinchonan-9-ole zur behandlung von coronavirus-infektionen
EP4104856A4 (de) Verwendung von anti-pd-1-antikörper zur behandlung von tumoren
EP4404931C0 (de) Azoloverbindungen zur behandlung von fibrotischen erkrankungen
EP4166138C0 (de) Verwendung von bromphenol-pyrazolin-verbindungen zur behandlung von felinen coronaviruserkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240123

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 11/00 20060101ALI20240117BHEP

Ipc: A61P 31/14 20060101ALI20240117BHEP

Ipc: A61K 31/5415 20060101ALI20240117BHEP

Ipc: A61K 31/4706 20060101AFI20240117BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20250307